A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, placebo-controlled study, enrolling approximately 38 healthy
adult subjects (18-65 yrs). The purpose of this study is to evaluate the safety, tolerability
and PK of single ascending dose of 9MW1911 administered intravenously (IV) in healthy adult
volunteers. All subjects will be followed up for safety from the time of Informed Consent
through 113 days post dose.